EGFR and non-small cell lung carcinoma: Some of third-generation EGFR-TKIs such as osimertinib [22]and nazartinib, which was formerly called EGF816, have demonstrated clinically significant efficacy and safety in NSCLC patients harboring EGFR T790M mutations, although the development of other third-generation candidates (rociletinib, olmutinib and naquotinib) has been halted [23, 24].